Literature DB >> 9247390

Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia.

P Pietrini1, A Dani, M L Furey, G E Alexander, U Freo, C L Grady, M J Mentis, D Mangot, E W Simon, B Horwitz, J V Haxby, M B Schapiro.   

Abstract

OBJECTIVE: Down's syndrome is characterized by the genetically programmed accumulation of substantial Alzheimer's disease neuropathology after age 40 and the development of early dementia years later, providing a unique human model to investigate the preclinical phases of Alzheimer's disease. Older nondemented adults with Down's syndrome show normal rates of regional cerebral glucose metabolism at rest before the onset of dementia, indicating that their neurons maintain function at rest. The authors hypothesized that an audiovisual stimulation paradigm, acting as a stress test, would reveal abnormalities in cerebral glucose metabolism before dementia in the neocortical parietal and temporal areas most vulnerable to Alzheimer's disease.
METHOD: Regional cerebral glucose metabolism was assessed by means of positron emission tomography (PET) with [18F]fluorodeoxyglucose in eight younger (mean age = 35 years, SD = 2) and eight older (mean age = 50, SD = 7) healthy, nondemented adults with trisomy 21 Down's syndrome. PET scans were performed at rest and during audiovisual stimulation in the same scanning session. Levels of general intellectual functioning and compliance were similar in the two groups.
RESULTS: At rest the two groups showed no difference in glucose metabolism in any cerebral region. In contrast, during audiovisual stimulation the older subjects with Down's syndrome had significantly lower glucose metabolic rates in the parietal and temporal cortical areas.
CONCLUSIONS: Abnormalities in cerebral metabolism during stimulation appeared in the first cortical regions typically affected in Alzheimer's disease. These results indicate that a stress test paradigm can detect metabolic abnormalities in the preclinical stages of Alzheimer's disease despite normal cerebral metabolism at rest.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247390     DOI: 10.1176/ajp.154.8.1063

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events.

Authors:  R J Haier; K Head; E Head; I T Lott
Journal:  Neuroimage       Date:  2007-10-12       Impact factor: 6.556

2.  Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

Authors:  Marwan N Sabbagh; Kewei Chen; Joseph Rogers; Adam S Fleisher; Carolyn Liebsack; Dan Bandy; Christine Belden; Hillary Protas; Pradeep Thiyyagura; Xiaofen Liu; Auttawut Roontiva; Ji Luo; Sandra Jacobson; Michael Malek-Ahmadi; Jessica Powell; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2015-04-04       Impact factor: 21.566

3.  Cognitive impairment and EEG background activity in adults with Down's syndrome: a topographic study.

Authors:  Svetla Velikova; Giuseppe Magnani; Claudia Arcari; Monica Falautano; Massimo Franceschi; Giancarlo Comi; Letizia Leocani
Journal:  Hum Brain Mapp       Date:  2011-05       Impact factor: 5.038

4.  Metabolic Dysfunction of Astrocyte: An Initiating Factor in Beta-amyloid Pathology?

Authors:  Liang-Jun Yan; Ming Xiao; Ran Chen; Zhiyou Cai
Journal:  Aging Neurodegener       Date:  2013-08

5.  Quantitative proteomics analysis of inborn errors of cholesterol synthesis: identification of altered metabolic pathways in DHCR7 and SC5D deficiency.

Authors:  Xiao-Sheng Jiang; Peter S Backlund; Christopher A Wassif; Alfred L Yergey; Forbes D Porter
Journal:  Mol Cell Proteomics       Date:  2010-03-19       Impact factor: 5.911

Review 6.  A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease.

Authors:  Marc Wermke; Christian Sorg; Afra M Wohlschläger; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

7.  Alzheimer's Disease in Down Syndrome.

Authors:  Elizabeth Head; David Powell; Brian T Gold; Frederick A Schmitt
Journal:  Eur J Neurodegener Dis       Date:  2012-12

Review 8.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

9.  The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome.

Authors:  Michael S Rafii; Hannah Wishnek; James B Brewer; Michael C Donohue; Seth Ness; William C Mobley; Paul S Aisen; Robert A Rissman
Journal:  Front Behav Neurosci       Date:  2015-09-14       Impact factor: 3.558

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.